Lipo-Peptides/Saccharides for Peptide Vaccine Delivery

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 571-579

  Skwarczynski, Mariusz ^a   Zaman, Mehfuz ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884957430     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00078-6     Document Type: Chapter

References (35)

1. Abdel-Aal A.B.M., Batzloff M.R., Fujita Y., Barozzi N., Faria A., Simerska P., et al. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group A streptococcal vaccine candidates. J Med Chem 2008, 51:167-172.
2. Abdel-Aal A.B.M., Zaman M., Fujita Y., Batzloff M.R., Good M.F., Toth I. Design of three-component vaccines against group a streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem 2010, 53:8041-8046.
3. Batzloff M.R., Sriprakash K.S., Good M.F. Vaccine development for group a Streptococcus infections and associated diseases. Curr Drug Targets 2004, 5:57-69.
4. Brown L.E., Jackson D.C. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2005, 2:383-393.
5. Fujita Y., Abdel-Aal A.B.M., Wimmer N., Batzloff M.R., Good M.F., Toth I. Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem 2008, 16:8907-8913.
6. Gibbons W.A., Hughes R.A., Charalambous M., Christodoulou M., Szeto A., Aulabaugh A.E., et al. Lipidic peptides.1. Synthesis, resolution and structural elucidation of lipidic amino-acids and their homo-oligomers and heterooligomers. Liebigs Ann Chem 1990, 1175-1183.
7. Hayman W.A., Toth I., Flinn N., Scanlon M., Good M.F. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002, 80:178-187.
8. Hennessy E.J., Parker A.E., O'Neill L.A.J. Targeting toll-like receptors: emerging therapeutics?. Nat Rev Drug Discovery 2010, 9:293-307.
9. Horvath A., Olive C., Karpati L., Sun H.K., Good M., Toth I. Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem 2004, 47:4100-4104.
10. Horvath A., Olive C., Wong A., Clair T., Yarwood P., Good M., et al. Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes. J Med Chem 2002, 45:1387-1390.
11. Irache J.M., Salman H.H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Exp Opin Drug Deliv 2008, 5:703-724.
12. Moyle P.M., Horvath A., Olive C., Good M.F., Toth I. Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. Lett Pept Sci 2003, 10:605-613.
13. Moyle P.M., Olive C., Ho M.F., Burgess M., Karpati L., Good M.F., et al. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. J Org Chem 2006, 71:6846-6850.
14. Moyle P.M., Olive C., Ho M.F., Good M.F., Toth I. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 2006, 49:6364-6370.
15. Moyle P.M., Olive C., Ho M.F., Pandey M., Dyer J., Suhrbier A., et al. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem 2007, 50:4721-4727.
16. Moyle P.M. Toth I self-adjuvanting lipopeptide vaccines. Curr Med Chem 2008, 15:506-516.
17. Olive C., Batzloff M., Horvath A., Clair T., Yarwood P., Toth I., et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003, 71:2373-2383.
18. Olive C., Ho M.F., Dyer J., Lincoln D., Barozzi N., Toth I., et al. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A Streptococcus. J Infect Dis 2006, 193:1666-1676.
19. Olive C., Schulze K., Sun H.K., Ebensen T., Horvath A., Toth I., et al. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 2007, 25:1789-1797.
20. Olive C., Sun H.K., Ho M.F., Dyer J., Horvath A., Toth I., et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006, 194:316-324.
21. Phillipps K.S., Wykes M.N., Liu X.Q., Brown M., Blanchfield J., Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 2009, 128(Suppl. 1):e582-e588.
22. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discovery 2007, 6:404-414.
23. Simerska P., Abdel-Aal A.B.M., Fujita Y., Moyle P.M., McGeary R.P., Batzloff M.R., et al. Development of a liposaccharide-based delivery system and its application to the design of group a streptococcal vaccines. J Med Chem 2008, 51:1447-1452.
24. Simerska P., Moyle P.M., Toth I. Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev 2011, 31:520-547.
25. Skwarczynski M., Ahmad Fuaad A.A.H., Rustanti L., Ziora Z.M., Aqil M., Batzloff M.R., et al. Group A streptococcal vaccine candidates based on the conserved conformational epitope from M protein. Drug Deliv Lett 2011, 1:2-8.
26. Skwarczynski M., Hayashi Y., Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem 2006, 49:7253-7269.
27. Skwarczynski M., Parhiz B.H., Soltani F., Srinivasan S., Kamaruzaman K.A., Lin I.C., et al. Lipid peptide core nanoparticles as multivalent vaccine candidates against Streptococcus pyogenes. Aust J Chem 2011, early view.
28. Skwarczynski M., Skwarczynski I. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Bioconjugation protocols: strategies and methods 2011, vo. 751. Springer p. 297-308. 2nd ed.
29. Skwarczynski M., Zaman M., Urbani C.N., Lin I.C., Jia Z.F., Batzloff M.R., et al. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed Engl 2010, 49:5742-5745.
30. Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv 2011, 8:282-289.
31. Zaman M., Abdel-Aal A.M., Phillipps K.S.M., Fujita Y., Good M.F., Toth I. Structure-activity relationship of lipopeptide group A Streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine 2010, 28:2243-2248.
32. Zaman M., Skwarczynski M. Toth I toll-like receptor 2 mediated dendritic cell activation-key target for lipopeptide vaccines design. Dendritic cells: types, life cycles and biological functions 2010, 63-80. Nova Science Publishers Inc., New York. L.C. Welles (Ed.).
33. Skwarczynski M., Malcolm J.M., Urbani C.N., Jia Z.F., Batzloff M.R., Good M.F., et al. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomed-Nanotechnol Biol Med 2011, 7:168-173.
34. Zhong W., Skwarczynski M., Toth I. Lipid core peptide system for gene, drug, and vaccine delivery. Aust J Chem 2009, 62:956-967.
35. Zhong G.M., Toth I., Reid R., Brunham R.C. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for chlamydia-trachomatis. J Immunol 1993, 151:3728-3736.